EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC
<p>5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Ki...
Saved in:
Main Author: | Fabio Villa (Author) |
---|---|
Format: | Book |
Published: |
Journal of Surgery and Surgical Research - Peertechz Publications,
2015-12-17.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neoadjuvant Chemotherapy Current Applications in Clinical Practice
Published: (2012) -
Neoadjuvant Chemotherapy Increasing Relevance in Cancer Management
Published: (2013) -
The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
by: Barbara Melosky
Published: (2015) -
Effect of processing variables on adsorption of DTP-JE antigens on adjuvant
by: Supranee Pradubpongsa
Published: (2014) -
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
by: Barbara Melosky
Published: (2018)